TriSalus Life Sciences Inc Dossier - Source-backed chat

TriSalus Life Sciences Inc

TLSINASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.62

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.31Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $265.4M

Enterprise Value $278M

Shares Outstanding 61.4M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

TriSalus Life Sciences is an oncology-focused medical technology company positioned for high growth, driven by its proprietary Pressure-Enabled Drug Delivery (PEDD) platform and the TriNav system. Despite a minor year-over-year revenue dip in Q1 2026 due to commercial expansion activities, the company maintains best-in-class gross margins of 86.2% and has strengthened its balance sheet with a $46 million equity raise, ending Q1 2026 with $56.6 million in cash. The long-term investment case is supported by robust real-world clinical evidence demonstrating fewer post-procedure complications and significant per-patient cost savings, paving the way for cash flow positivity by 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$9.00

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0015%

Commercial expansion fails to generate expected sales volumes, or the company faces hurdles in brand recognition and clinical adoption. Slower-than-expected market penetration and high cash burn from sales and marketing expenses delay the path to profitability beyond 2027.

Base CaseCentral scenario

$8.0060%

TriNav system adoption continues steadily within liver-directed therapies, meeting the revised FY 2026 revenue guidance of $54 million to $57 million. Gross margins remain stable in the mid-80s, and the company achieves cash flow positivity by 2027 as planned.

Bull CaseUpside scenario

$11.0025%

Rapid market share expansion of the TriNav and TriNav LV systems, combined with successful clinical milestones for the investigational immunotherapeutic nelitolimod, drives revenue to the high end of expectations. Operating leverage improves faster than anticipated, leading to early cash flow positivity before 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary Pressure-Enabled Drug Delivery (PEDD) technology addresses anatomical barriers in solid tumors, improving therapeutic delivery.
Best-in-class gross margins (86.2% in Q1 2026) provide strong operating leverage potential.
Robust real-world clinical data shows improved outcomes, fewer complications, and approximately $7,700 in per-patient charge avoidance.
Strengthened balance sheet with $56.6 million in cash as of March 31, 2026, following a successful $46 million equity offering.

Key Investment Risks

Revised FY 2026 revenue guidance ($54M-$57M) down from initial projections ($60M-$62M) highlights commercial execution risks.
Ongoing operating losses ($8.4 million in Q1 2026) driven by high sales, marketing, and commercial expansion expenses.
Potential challenges in achieving widespread market acceptance and brand recognition among interventional radiologists.

Thesis Invalidation Triggers

Failure to meet the revised FY 2026 revenue guidance of $54 million to $57 million.
Significant deterioration of gross margins below 80%.
Clinical trial setbacks or negative data readouts for the nelitolimod program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.